Highlights Profound Medical Corp.

Equities

PRN

CA74319B5027

Market Closed - Toronto S.E. Other stock markets 03:59:24 2024-05-24 pm EDT			5-day change	1st Jan Change
10.08 ^CAD	-0.69%		-9.92%	-9.19%

May. 15	Transcript : Profound Medical Corp. - Shareholder/Analyst Call
May. 14	Sector Update: Health Care Stocks Steady Premarket Tuesday	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Steady Premarket Tuesday	May. 14	MT
Profound Medical Receives U.S. FDA Clearance for "Contouring Assistant" AI Module	May. 14	MT
Profound Medical Brief: Says Received U.S. FDA 510(k) Clearance for 'Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan	May. 14	MT
Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan	May. 14	CI
Profound Reports a Narrower First-Quarter Loss; Provides 2024 Revenue Guidance	May. 09	MT
Profound Medical Brief: Expects total revenue for FY24 to be in the range of US$11.0-$12.0 million, which represents 53% to 67% growth compared to its prior year revenue	May. 09	MT
Profound Medical Brief: Recorded Q1 revenue of approximately $1.91 million, with $1.48 million from recurring revenue; Issues Full-Year 2024 Revenue Guidance	May. 09	MT
Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024	May. 09	CI
Profound Medical Says Clinical Evidence Points to Potential of Its TULSA Procedure as a Treatment for Prostate Cancer	May. 06	MT
Profound Medical Brief: Adds Clinical evidence Continues to highlight TULSA's "Ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH"	May. 06	MT
Profound Medical Brief: Says "Growing Body of Clinical Evidence" Points to Potential of Its TULSA Procedure "Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum"	May. 06	MT
Profound Medical Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Profound Medical Reports Q4 Net Loss of US$0.42 Per Share, Announces COO Appointment	Mar. 07	MT
Profound Medical Brief: Announcing promotion of Mathieu Burtnyk, from SVP Product Leader to Chief Operating Officer	Mar. 07	MT
Profound Medical Brief: Q4 2023 net loss was approximately US$8.9 million, or $0.42 per common share	Mar. 07	MT
Profound Medical Collaborates With Siemens Healthineers to Expand Physician and Patient Access to the TULSA Procedure	Feb. 27	MT
Profound Medical Corp. Enters into A Non-Exclusive Collaboration with Siemens Healthineers	Feb. 27	CI
Profound Medical Brief: Entering Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure	Feb. 27	MT
Profound Medical Brief: Adds Top priorities for 2024 will be to further increase Its TULSA-PRO installed base, support increased system utilization, complete its ongoing Level 1 CAPTAIN trial	Jan. 03	MT
Profound Medical Brief: For Full year 2023, Anticipates total revenues to be in Approximate range of US$7.1 million to $7.2 million	Jan. 03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Profound Medical Corp.

Equities

PRN

CA74319B5027

Highlights

Filters